Univariate analysis for disease free survival and overall survival
| DFS | OS | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age at diagnosis (years) | 1.00 (0.98 to 1.02) | 0.897 | 1.00 (0.97 to 1.02) | 0.928 |
| Body mass index | 0.98 (0.93 to 1.02) | 0.329 | 0.96 (0.91 to 1.02) | 0.184 |
| Pre-therapeutic tumor size (cm) | 1.12 (1.00 to 1.25) | 0.052 | 1.09 (0.94 to 1.27) | 0.234 |
| Tumor size post EBRT (cm) | 1.38 (1.19 to 1.60) | <0.001 | 1.25 (1.07 to 1.47) | 0.005 |
| Tumor size reduction rate (%) | 0.99 (0.98 to 1.00) | 0.002 | 0.99 (0.98 to 1.00) | 0.049 |
| Duration of treatment with EBRT + BT (days) | 1.01 (1.00 to 1.02) | 0.075 | 1.01 (1.00 to 1.03) | 0.025 |
| Comorbidity | 1.36 (0.82 to 2.24) | 0.228 | 1.33 (0.73 to 2.41) | 0.347 |
| Histology type (squamous vs other) | 0.91 (0.51 to 1.62) | 0.738 | 0.79 (0.41 to 1.54) | 0.492 |
| Clinical staging (IIB-IIIB vs IB2-IIA) | 1.59 (0.98 to 2.57) | 0.058 | 1.45 (0.82 to 2.57) | 0.199 |
| MRI staging (IIB-IVA vs IB2-IIA) | 1.78 (0.97 to 3.27) | 0.057 | 1.37 (0.70 to 2.70) | 0.356 |
| Parametrial invasion | 1.66 (0.93 to 2.95) | 0.081 | 1.38 (0.72 to 2.65) | 0.330 |
| Type of treatment post MRI (BT alone vs other) | 0.77 (0.43 to 1.35) | 0.356 | 0.70 (0.36 to 1.36) | 0.289 |
| Residual tumor at post-EBRT MRI | 1.62 (0.93 to 2.82) | 0.084 | 1.30 (0.70 to 2.43) | 0.409 |
| Total radiotherapy received ≥80 Gy vs <80 Gy | 1.02 (0.54 to 1.91) | 0.958 | 1.13 (0.53 to 2.40) | 0.751 |
| Tumor size reduction rate ≥50% vs <50% | 0.73 (0.45 to 1.18) | 0.191 | 0.81 (0.45 to 1.44) | 0.462 |
| Tumor size reduction rate ≥60% vs <60% | 0.48 (0.30 to 0.77) | 0.002 | 0.51 (0.29 to 0.88) | 0.014 |
| Tumor size reduction rate ≥80% vs <80% | 0.66 (0.40 to 1.09) | 0.105 | 0.83 (0.46 to 1.48) | 0.524 |
BT, brachytherapy; DFS, disease free survival; EBRT, external beam radiotherapy; HR, hazard ratio; OS, overall survival.